SAB BIOTHERAPEUTICS, INC. (SABS) Current Ratio
- Current ratio · latest quarter: Value 9.22×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.22× | Current assets / current liabilities. $107.94M ÷ $11.71M ≈ 9.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 107.94M USD | Assets, Current |
| Current obligations | 11.71M USD | Liabilities, Current |
| Cash and equivalents | 8.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 3.85M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $107.94M | $11.71M | $8.27M | (m) | (m) | (m) | $3.85M | (m) | 9.22× |
| 2026-03-31 | $112.78M | $9.85M | $20.52M | (m) | (m) | (m) | $3.54M | (m) | 11.45× |
| 2025-12-31 | $101.05M | $10.68M | $10.50M | (m) | (m) | (m) | $3.15M | (m) | 9.46× |
| 2025-09-30 | $113.28M | $10.79M | $29.42M | (m) | (m) | (m) | $2.95M | (m) | 10.50× |
| 2025-06-30 | $9.31M | $10.68M | $3.69M | (m) | (m) | (m) | $2.62M | (m) | 0.87× |
| 2025-03-31 | $16.30M | $9.65M | $5.64M | (m) | (m) | (m) | $2.52M | (m) | 1.69× |
| 2024-12-31 | $23.79M | $7.98M | $8.90M | (m) | (m) | (m) | $1.69M | (m) | 2.98× |
| 2024-09-30 | $32.54M | $8.82M | $9.17M | (m) | (m) | (m) | $1.30M | (m) | 3.69× |
| 2024-06-30 | $39.58M | $7.55M | $17.24M | (m) | (m) | (m) | $1.17M | (m) | 5.24× |
| 2024-03-31 | $46.95M | $8.30M | $14.03M | (m) | (m) | (m) | $1.24M | (m) | 5.65× |
| 2023-12-31 | $58.91M | $10.81M | $56.57M | (m) | (m) | (m) | $945.93K | (m) | 5.45× |
| 2023-09-30 | $3.13M | $9.21M | $2.43M | (m) | $0.00 | (m) | $1.08M | (m) | 0.34× |
| 2023-06-30 | $9.01M | $11.01M | $7.77M | (m) | $364.12K | (m) | $1.40M | (m) | 0.82× |
| 2023-03-31 | $15.03M | $13.67M | $13.06M | (m) | $763.12K | (m) | $1.44M | (m) | 1.10× |
| 2022-12-31 | $22.10M | $14.99M | $15.05M | (m) | $5.56M | (m) | $3.68M | (m) | 1.47× |
| 2022-09-30 | $22.18M | $17.10M | $8.33M | (m) | (m) | (m) | $5.48M | (m) | 1.30× |
| 2022-06-30 | $28.00M | $16.39M | $16.62M | (m) | $9.61M | (m) | $4.94M | (m) | 1.71× |
| 2022-03-31 | $37.18M | $19.27M | $22.41M | (m) | $11.79M | (m) | $4.98M | (m) | 1.93× |
| 2021-12-31 | $50.19M | $26.46M | $33.21M | (m) | $8.01M | (m) | $4.46M | (m) | 1.90× |
| 2021-09-30 | $770.62K | $322.38K | (m) | (m) | (m) | (m) | (m) | (m) | 2.39× |
| 2021-06-30 | $936.67K | $152.88K | (m) | (m) | (m) | (m) | (m) | (m) | 6.13× |
| 2021-03-31 | $1.12M | $80.00K | (m) | (m) | (m) | (m) | (m) | (m) | 14.01× |
| 2020-12-31 | $34.46M | $11.06M | $12.61M | (m) | $20.57M | (m) | $7.38M | (m) | 3.11× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |